VOLITIONRX LTD — Form 8-K
Filed September 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
VolitionRx secured a waiver and consent from Lind Global Asset Management XII LLC dated September 2, 2026, permitting unlimited sales under its ATM (at-the-market) offering agreement without triggering default or anti-dilution adjustments on $9.9M in convertible notes and warrants held by Lind. The company previously faced a $10M annual cap on ATM sales; this waiver removes that constraint and waives Lind's remedies for prior above-cap sales occurring before August 28, 2026. Conversion price fixed at $0.44 and warrant exercise price at $0.572.
Why this rating
Removes capital-raising constraints for a $73M market-cap company facing $9.9M debt; eliminates default/anti-dilution risk. Material near-term financing flexibility, though dependent on market conditions.
Tradability signal
NO TRADE
No trade: price $0.38 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.37 ▼ 2.18% | at our read · unknown $0.38 | +10 min · unknown $0.38 ▲ 0.00% | +30 min · unknown $0.38 ▲ 0.00% | +1 hr · unknown $0.38 ▲ 0.00% | +4 hrs pending |
The stock had already moved +2.23% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.